Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

Study ID
NCT02872116

Study type
Interventional

Study phase
Phase 3

Study status
Active, not recruiting

Trial Acronym

CheckMate649

Trial Summary

The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving chemotherapy alone.

More informations

Trial Starting Date

Oct 12,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

2031